17-AAG inhibits vemurafenib-associated MAP kinase activation and is synergistic with cellular immunotherapy in a murine melanoma model.
Heat shock protein 90 (HSP90) is a molecular chaperone which stabilizes client proteins with important roles in tumor growth. 17-allylamino-17-demethoxygeldanamycin (17-AAG), an inhibitor of HSP90 ATPase activity, occupies the ATP binding site of HSP90 causing a conformational change which destabili...
Main Authors: | Sandeep S Joshi, Shunlin Jiang, Emmanual Unni, Stephen R Goding, Tao Fan, Paul A Antony, Thomas J Hornyak |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2018-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC5826531?pdf=render |
Similar Items
-
VEMURAFENIB IN TREATMENT OF MELANOMA WITH BRAIN METASTASES
by: D. R. Naskhletashvili, et al.
Published: (2017-04-01) -
Metastatic melanoma and vemurafenib: novel approaches
by: Ramon Andrade De Mello
Published: (2012-04-01) -
Melanoma Cell Resistance to Vemurafenib Modifies Inter-Cellular Communication Signals
by: Claudio Tabolacci, et al.
Published: (2021-01-01) -
Role of vemurafenib in the treatment of disseminated skin melanoma
by: L V Demidov, et al.
Published: (2013-06-01) -
A Smart Hyperthermia Nanofiber-Platform-Enabled Sustained Release of Doxorubicin and 17AAG for Synergistic Cancer Therapy
by: Lili Chen, et al.
Published: (2021-03-01)